|Moderated by: Prof Trevor Marshall||Topic closed|
Prof Trevor Marshall
"Out of 1,167,482 surgical admissions, 30,173 inpatient surgical admissions met inclusion criteria. Approximately 10,205 patients (33.8%) in the cohort did not resume ARB by day 2. Those that resumed ARB had a 30-day mortality rate of 1.3% (260 of 19,968), whereas 3.2% (323 of 10,205) died in the group that withheld ARB. The unadjusted hazard ratio (HR) for 30-day mortality was 2.45 for those that withheld ARB compared with those that resumed"
A new paper has also come out confirming that Olmesartan actually reduced plaque deposits in the 'MORE' study:
|This is one of those times I wish this platform had a like button.
* We can help you understand chronic disease, but only your physician is licensed to give you medical care *Powered by - Entire site Copyright © 2004-2021 Autoimmunity Research Foundation, All Rights Reserved